Premphase Prempro
Name: Premphase Prempro
- Premphase Prempro mg
- Premphase Prempro tablet
- Premphase Prempro drug
- Premphase Prempro effects of
- Premphase Prempro the effects of
- Premphase Prempro mg tablet
- Premphase Prempro side effects
- Premphase Prempro missed dose
Adverse Reactions
The following serious adverse reactions are discussed elsewhere in the labeling:
- Cardiovascular Disorders [see Boxed Warning, Warnings and Precautions (5.1)]
- Malignant Neoplasms [see Boxed Warning, Warnings and Precautions (5.2)]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a 1-year clinical trial that included 678 postmenopausal women treated with PREMPRO and 351 postmenopausal women treated with PREMPHASE, the following adverse reactions occurred at a rate ≥ 1 percent, see Table 1.
| Body System | PREMPRO 0.625 mg/2.5 mg continuous | PREMPRO 0.625 mg/5 mg continuous | PREMPHASE 0.625 mg/5 mg sequential |
|---|---|---|---|
| Adverse event | (n = 340) | (n = 338) | (n = 351) |
| Body As A Whole | |||
| Abdominal pain | 35 (10%) | 51 (15%) | 58 (17%) |
| Asthenia | 13 (4%) | 18 (5%) | 21 (6%) |
| Back pain | 19 (6%) | 16 (5%) | 23 (7%) |
| Chest pain | 5 (1%) | 4 (1%) | 4 (1%) |
| Flu syndrome | 1 (<1%) | 1 (<1%) | 4 (1%) |
| Generalized edema | 12 (4%) | 12 (4%) | 8 (2%) |
| Headache | 64 (19%) | 52 (15%) | 66 (19%) |
| Infection | 2 (<1%) | 4 (1)% | 0 |
| Moniliasis | 4 (1%) | 3 (<1%) | 4 (1%) |
| Pain | 12 (4%) | 14 (4%) | 15 (4%) |
| Pelvic pain | 11 (3%) | 13 (4%) | 16 (5%) |
| Cardiovascular System | |||
| Hypertension | 7 (2%) | 7 (2%) | 6 (2%) |
| Migraine | 6 (2%) | 8 (2%) | 7 (2%) |
| Palpitation | 2 (<1%) | 3 (<1%) | 4 (1%) |
| Vasodilatation | 2 (<1%) | 7 (2%) | 2 (<1%) |
| Digestive System | |||
| Diarrhea | 4 (1%) | 3 (<1%) | 7 (2%) |
| Dyspepsia | 5 (1%) | 5 (1%) | 7 (2%) |
| Eructation | 0 | 2 (<1%) | 4 (1%) |
| Flatulence | 25 (7%) | 27 (8%) | 24 (7%) |
| Increased appetite | 1 (<1%) | 5 (1%) | 5 (1%) |
| Nausea | 26 (8%) | 19 (6%) | 26 (7%) |
| Metabolic and Nutritional | |||
| Edema | 5 (1%) | 6 (2%) | 3 (<1%) |
| Glucose tolerance decreased | 2 (<1%) | 5 (1%) | 4 (1%) |
| Peripheral edema | 11 (3%) | 10 (3%) | 11 (3%) |
| Weight gain | 9 (3%) | 10 (3%) | 11 (3%) |
| Musculoskeletal System | |||
| Arthralgia | 6 (2%) | 2 (<1%) | 7 (2%) |
| Leg cramps | 8 (2%) | 11 (3%) | 12 (3%) |
| Nervous System | |||
| Depression | 14 (4%) | 26 (8%) | 29 (8%) |
| Dizziness | 9 (3%) | 8 (2%) | 7 (2%) |
| Emotional lability | 5 (1%) | 5 (1%) | 6 (2%) |
| Hypertonia | 4 (1%) | 4 (1%) | 7 (2%) |
| Insomnia | 7 (2%) | 6 (2%) | 4 (1%) |
| Nervousness | 4 (1%) | 9 (3%) | 6 (2%) |
| Skin and Appendages | |||
| Acne | 1 (<1%) | 5 (1%) | 4 (1%) |
| Alopecia | 3 (<1%) | 4 (1%) | 0 |
| Dry skin | 2 (<1%) | 3 (<1%) | 4 (1%) |
| Pruritus | 20 (6%) | 18 (5%) | 13 (4%) |
| Rash | 8 (2%) | 6 (2%) | 7 (2%) |
| Sweating | 2 (<1%) | 4 (1%) | 2 (<1%) |
| Urogenital System | |||
| Breast engorgement | 5 (1%) | 5 (1%) | 0 |
| Breast enlargement | 14 (4%) | 14 (4%) | 14 (4%) |
| Breast neoplasm | 2 (<1%) | 2 (<1%) | 4 (1%) |
| Breast pain | 110 (32%) | 123 (36%) | 109 (31%) |
| Cervix disorder | 10 (3%) | 6 (2%) | 10 (3%) |
| Dysmenorrhea | 26 (8%) | 18 (5%) | 44 (13%) |
| Leukorrhea | 19 (6%) | 13 (4%) | 29 (8%) |
| Menstrual disorder | 7 (2%) | 1 (<1%) | 5 (1%) |
| Menorrhagia | 0 | 1 (<1%) | 5 (1%) |
| Metrorrhagia | 13 (4%) | 5 (1%) | 7 (1%) |
| Papanicolaou smear suspicious | 5 (1%) | 0 | 8 (2%) |
| Urinary incontinence | 4 (1%) | 2 (<1%) | 1 (<1%) |
| Uterine spasm | 7 (2%) | 4 (1%) | 7 (2%) |
| Vaginal hemorrhage | 5 (1%) | 3 (<1%) | 8 (2%) |
| Vaginal moniliasis | 5 (1%) | 6 (2%) | 7 (2%) |
| Vaginitis | 13 (4%) | 13 (4%) | 10 (3%) |
In addition, phargyngitis and sinusitis were reported as two of the more frequent adverse events (>5 percent) in the PREMPRO clinical study. For pharyngitis, of the 121 events, six events were considered by the investigator causally related to study drug. For sinusitis, of the 73 events, one event was considered as casually related to study drug.
During the first year of a 2-year clinical trial with postmenopausal women between 40 and 65 years of age (88 percent Caucasian), 989 postmenopausal women received continuous regimens of PREMPRO, and 332 received placebo tablets. Table 2 summarizes adverse reactions that occurred at a rate ≥ 1 percent in at least 1 treatment group.
Body System Adverse event | PREMPRO 0.625/2.5 continuous (N=331) | PREMPRO 0.45/1.5 continuous (N=331) | PREMPRO 0.3/1.5 continuous (N=327) | PLACEBO daily (N=332) |
|---|---|---|---|---|
| Any adverse event | 214 (65) | 208 (63) | 188 (57) | 164 (49) |
| Body as a Whole | ||||
| Abdominal pain | 38 (11) | 33 (10) | 24 (7) | 21 (6) |
| Asthenia | 11 (3) | 11 (3) | 12 (4) | 3 (1) |
| Back pain | 12 (4) | 12 (4) | 8 (2) | 4 (1) |
| Chest pain | 4 (1) | 2 (1) | 1 (0) | 2 (1) |
| Generalized edema | 7 (2) | 5 (2) | 6 (2) | 8 (2) |
| Headache | 45 (14) | 45 (14) | 57 (17) | 46 (14) |
| Moniliasis | 3 (1) | 6 (2) | 4 (1) | 1 (0) |
| Pain | 9 (3) | 10 (3) | 17 (5) | 14 (4) |
| Pelvic pain | 9 (3) | 7 (2) | 5 (2) | 4 (1) |
| Cardiovascular System | ||||
| Hypertension | 2 (1) | 3 (1) | 1 (0) | 5 (2) |
| Migraine | 11 (3) | 8 (2) | 5 (2) | 3 (1) |
| Palpitation | 1 (0) | 1 (0) | 2 (1) | 4 (1) |
| Vasodilatation | 0 | 3 (1) | 1 (0) | 5 (2) |
| Digestive System | ||||
| Constipation | 5 (2) | 7 (2) | 6 (2) | 3 (1) |
| Diarrhea | 5 (2) | 2 (1) | 6 (2) | 8 (2) |
| Dyspepsia | 10 (3) | 9 (3) | 6 (2) | 14 (4) |
| Flatulence | 16 (5) | 18 (5) | 13 (4) | 8 (2) |
| Increased appetite | 6 (2) | 2 (1) | 0 | 2 (1) |
| Nausea | 13 (4) | 13 (4) | 16 (5) | 16 (5) |
| Metabolic and nutritional | ||||
| Peripheral edema | 7 (2) | 8 (2) | 4 (1) | 3 (1) |
| Weight gain | 9 (3) | 8 (2) | 6 (2) | 14 (4) |
| Musculoskeletal System | ||||
| Arthralgia | 2 (1) | 3 (1) | 3 (1) | 5 (2) |
| Leg cramps | 13 (4) | 7 (2) | 10 (3) | 4 (1) |
| Nervous System | ||||
| Anxiety | 5 (2) | 4 (1) | 1 (0) | 4 (1) |
| Depression | 23 (7) | 11 (3) | 11 (3) | 17 (5) |
| Dizziness | 3 (1) | 8 (2) | 6 (2) | 5 (2) |
| Emotional lability | 10 (3) | 10 (3) | 9 (3) | 8 (2) |
| Insomnia | 8 (2) | 7 (2) | 9 (3) | 14 (4) |
| Nervousness | 6 (2) | 3 (1) | 4 (1) | 6 (2) |
| Skin and Appendages | ||||
| Acne | 7 (2) | 3 (1) | 0 | 3 (1) |
| Alopecia | 1 (0) | 6 (2) | 4 (1) | 2 (1) |
| Pruritus | 8 (2) | 10 (3) | 9 (3) | 3 (1) |
| Rash | 0 | 6 (2) | 4 (1) | 2 (1) |
| Skin discoloration | 5 (2) | 1 (0) | 3 (1) | 1 (0) |
| Sweating | 3 (1) | 1 (0) | 0 | 4 (1) |
| Urogenital System | ||||
| Breast disorder | 7 (2) | 6 (2) | 5 (2) | 6 (2) |
| Breast enlargement | 18 (5) | 9 (3) | 5 (2) | 3 (1) |
| Breast neoplasm | 8 (2) | 7 (2) | 5 (2) | 7 (2) |
| Breast pain | 87 (26) | 66 (20) | 41 (13) | 26 (8) |
| Cervix disorder | 7 (2) | 2 (1) | 2 (1) | 0 |
| Dysmenorrhea | 14 (4) | 18 (5) | 9 (3) | 2 (1) |
| Hematuria | 4 (1) | 3 (1) | 1 (0) | 2 (1) |
| Leukorrhea | 7 (2) | 14 (4) | 9 (3) | 6 (2) |
| Metrorrhagia | 7 (2) | 14 (4) | 4 (1) | 1 (0) |
| Urinary tract infection | 0 | 1 (0) | 1 (0) | 4 (1) |
| Uterine spasm | 13 (4) | 11 (3) | 7 (2) | 2 (1) |
| Vaginal dryness | 2 (1) | 1 (0) | 0 | 6 (2) |
| Vaginal hemorrhage | 18 (5) | 14 (4) | 7 (2) | 0 |
| Vaginal moniliasis | 13 (4) | 11 (3) | 8 (2) | 5 (2) |
| Vaginitis | 6 (2) | 8 (2) | 7 (2) | 1 (0) |
In addition, the following events were considered as related to the study drug with an incidence less than 1 percent, including accidental injury, infection, myalgia, cough increased, rhinitis, sinusitis, and upper respiratory infection.
Postmarketing Experience
The following adverse reactions have been identified during post-approval use of PREMPRO or PREMPHASE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Genitourinary System
Abnormal uterine bleeding, dysmenorrhea or pelvic pain, increase in size of uterine leiomyomata, vaginitis, vaginal candidiasis, amenorrhea, changes in cervical secretion, ovarian cancer, endometrial hyperplasia, endometrial cancer.
Breasts
Tenderness, enlargement, pain, nipple discharge, galactorrhea, fibrocystic breast changes, breast cancer.
Cardiovascular
Deep and superficial venous thrombosis, pulmonary embolism, superficial thrombophlebitis, myocardial infarction, stroke, increase in blood pressure.
Gastrointestinal
Nausea, vomiting, abdominal pain, bloating, cholestatic jaundice, increased incidence of gallbladder disease, pancreatitis, changes in appetite, ischemic colitis.
Skin
Chloasma or melasma that may persist when drug is discontinued, erythema multiforme, erythema nodosum, loss of scalp hair, hirsutism, pruritus, urticaria, rash, acne.
Eyes
Retinal vascular thrombosis, intolerance of contact lenses.
Central Nervous System
Headache, migraine, dizziness, mental depression, exacerbation of chorea, mood disturbances, anxiety, irritability, exacerbation of epilepsy, dementia, growth potentiation of benign meningioma.
Miscellaneous
Increase or decrease in weight, arthralgia, glucose intolerance, edema, changes in libido, exacerbation of asthma, increased triglycerides, hypersensitivity.
Additional postmarketing adverse reactions have been reported in patients receiving other forms of hormone therapy.
Use in specific populations
Pregnancy
PREMPRO and PREMPHASE should not be used during pregnancy [see Contraindications (4)]. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.
Nursing Mothers
PREMPRO and PREMPHASE should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogen and progestin have been identified in the breast milk of women receiving these drugs. Caution should be exercised when PREMPRO or PREMPHASE is administered to a nursing woman.
Pediatric Use
PREMPRO and PREMPHASE are not indicated in children. Clinical studies have not been conducted in the pediatric population.
Geriatric Use
There have not been sufficient numbers of geriatric women involved in clinical studies utilizing PREMPRO or PREMPHASE to determine whether those over 65 years of age differ from younger subjects in their response to PREMPRO or PREMPHASE.
The Women's Health Initiative Studies
In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see Clinical Studies (14.6)].
In the WHI estrogen-alone substudy (daily CE [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see Clinical Studies (14.6)].
The Women's Health Initiative Memory Study
In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin or estrogen-alone when compared to placebo [see Warnings and Precautions (5.3), and Clinical Studies (14.7)].
Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8 [see Warnings and Precautions (5.3), and Clinical Studies (14.7)].
Renal Impairment
The effects of renal impairment on the pharmacokinetics of PREMPRO or PREMPHASE have not been studied.
Hepatic Impairment
The effects of hepatic impairment on the pharmacokinetics of PREMPRO or PREMPHASE have not been studied.
Patient information
PREMPRO®
(Conjugated Estrogens/Medroxyprogesterone Acetate Tablets)
PREMPHASE®
(Conjugated Estrogens plus Medroxyprogesterone Acetate Tablets)
Read this PATIENT INFORMATION before you start taking PREMPRO or PREMPHASE and read what you get each time you refill your PREMPRO or PREMPHASE prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
What is the most important information I should know about PREMPRO and PREMPHASE (combinations of estrogens and a progestin)?
|
What is PREMPRO or PREMPHASE?
PREMPRO or PREMPHASE are medicines that contain two kinds of hormones, estrogens and a progestin.
What is PREMPRO or PREMPHASE used for?
PREMPRO or PREMPHASE is used after menopause to:
- Reduce moderate to severe hot flashes
Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the "change of life" or menopause (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural menopause takes place. The sudden drop in estrogen levels causes "surgical menopause."
When the estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and sweating ("hot flashes" or "hot flushes"). In some women the symptoms are mild, and they will not need to take estrogens. In other women, symptoms can be more severe. - Treat menopausal changes in and around the vagina
You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE to control these problems. If you use PREMPRO or PREMPHASE only to treat your menopausal changes in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you. - Help reduce your chances of getting osteoporosis (thin weak bones)
Osteoporosis from menopause is a thinning of the bones that makes them weaker and easier to break. If you use PREMPRO or PREMPHASE only to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. Weight-bearing exercise, like walking or running, and taking calcium (1500 mg per day of elemental calcium) and vitamin D (400–800 IU per day) supplements may also lower your chances of getting postmenopausal osteoporosis. It is important to talk about exercise and supplements with your healthcare provider before starting them.
You and your healthcare provider should talk regularly about whether you still need treatment with PREMPRO or PREMPHASE.
Who should not take PREMPRO or PREMPHASE?
Do not take PREMPRO or PREMPHASE if you have had your uterus (womb) removed (hysterectomy).
PREMPRO and PREMPHASE contain a progestin to decrease the chance of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not take PREMPRO or PREMPHASE.
Do not take PREMPRO or PREMPHASE if you:
- Have unusual vaginal bleeding
- Currently have or have had certain cancers
Estrogens may increase the chance of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should use PREMPRO or PREMPHASE. - Had a stroke or heart attack
- Currently have or have had blood clots
- Currently have or have had liver problems
- Have been diagnosed with a bleeding disorder
- Are allergic to PREMPRO or PREMPHASE or any of their ingredients
See the list of ingredients in PREMPRO and PREMPHASE at the end of this leaflet. - Think you may be pregnant
Tell your healthcare provider
- If you have any unusual vaginal bleeding
Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. - About all of your medical problems
Your healthcare provider may need to check you more carefully if you have certain conditions, such as asthma (wheezing), epilepsy (seizures), diabetes, migraine, endometriosis, lupus, problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood. - About all the medicines you take
This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how PREMPRO or PREMPHASE works. PREMPRO or PREMPHASE may also affect how your other medicines work. - If you are going to have surgery or will be on bedrest
You may need to stop taking PREMPRO or PREMPHASE. - If you are breastfeeding
The hormones in PREMPRO and PREMPHASE can pass into your breast milk.
How should I take PREMPRO or PREMPHASE?
- Take one PREMPRO or PREMPHASE tablet at the same time each day
- If you miss a dose, take it as soon as possible
If it is almost time for your next dose, skip the missed dose and go back to your normal schedule. Do not take 2 doses at the same time. - Estrogens should be used at the lowest dose possible for your treatment only as long as needed
You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with PREMPRO or PREMPHASE.
What are the possible side effects of PREMPRO or PREMPHASE?
Side effects are grouped by how serious they are and how often they happen when you are treated.
Serious, but less common side effects include:
- Heart attack
- Stroke
- Blood clots
- Dementia
- Breast cancer
- Cancer of the lining of the uterus (womb)
- Cancer of the ovary
- High blood pressure
- High blood sugar
- Gallbladder disease
- Liver problems
- Enlargement of benign tumors of the uterus ("fibroids")
- Mental depression
- Severe allergic reaction
Call your healthcare provider right away if you get any of the following warning signs or any other unusual symptoms that concern you:
- New breast lumps
- Unusual vaginal bleeding
- Changes in vision or speech
- Sudden new severe headaches
- Severe pains in your chest or legs with or without shortness of breath, weakness and fatigue
- Swollen lips, tongue and face
Less serious, but common side effects include:
- Headache
- Breast pain
- Irregular vaginal bleeding or spotting
- Stomach or abdominal cramps, bloating
- Nausea and vomiting
- Hair loss
- Fluid retention
- Vaginal yeast infection
These are not all the possible side effects of PREMPRO or PREMPHASE. For more information, ask your healthcare provider or pharmacist for advice about side effects. You may report side effects to Pfizer Inc. at 1-800-438-1985 or to FDA at 1-800-FDA-1088.
What can I do to lower my chances of getting a serious side effect with PREMPRO or PREMPHASE?
- Talk with your healthcare provider regularly about whether you should continue taking PREMPRO or PREMPHASE
- See your healthcare provider right away if you get vaginal bleeding while taking PREMPRO or PREMPHASE
- Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else
If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often. - If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease
Ask your healthcare provider for ways to lower your chances of getting heart disease.
General Information about the safe and effective use of PREMPRO and PREMPHASE
Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take PREMPRO or PREMPHASE for conditions for which it was not prescribed. Do not give PREMPRO or PREMPHASE to other people, even if they have the same symptoms you have. It may harm them.
Keep PREMPRO and PREMPHASE out of the reach of children.
This leaflet provides a summary of the most important information about PREMPRO and PREMPHASE. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about PREMPRO and PREMPHASE that is written for health professionals.
What are the ingredients in PREMPRO and PREMPHASE?
PREMPRO contains the same conjugated estrogens found in Premarin, which are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol and 17β-dihydroequilin. PREMPRO also contains either 1.5, 2.5, or 5 mg of medroxyprogesterone acetate.
PREMPRO 0.3 mg/1.5 mg and 0.45 mg/1.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, lactose monohydrate, carnauba wax, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, titanium dioxide, yellow iron oxide, propylene glycol and black iron oxide.
PREMPRO 0.625 mg/2.5 mg tablets also contain calcium phosphate tribasic, microcrystalline cellulose, lactose monohydrate, hypromellose, magnesium stearate, polyethylene glycol, sucrose, hydroxypropyl cellulose, Eudragit NE 30D, povidone, titanium dioxide, red iron oxide, yellow iron oxide, and black iron oxide.
PREMPRO 0.625 mg/5 mg tablets also contain calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, FD&C Blue No. 2, and black iron oxide.
PREMPHASE is two separate tablets. One tablet (maroon color) is 0.625 mg of Premarin, which is a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17 α-dihydroequilin, 17 α-estradiol and 17 β-dihydroequilin. The maroon tablet also contains calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, titanium dioxide, FD&C Blue No. 2, FD&C Red No. 40. The second tablet (light-blue color) contains 0.625 mg of the same ingredients as the maroon color tablet plus 5 mg of medroxyprogesterone acetate. The light-blue tablet also contains calcium phosphate tribasic, carnauba wax, Eudragit NE 30D, hydroxypropyl cellulose, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sucrose, titanium dioxide, FD&C Blue No. 2, and black iron oxide.
PREMPRO therapy consists of a single tablet to be taken once daily.
PREMPRO 0.3 mg/1.5 mg
Blister Card - Each carton includes 1 blister card containing 28 oval, cream tablets. Each tablet contains 0.3 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.
PREMPRO 0.45 mg/1.5 mg
Blister Card - Each carton includes 1 blister card containing 28 oval, gold tablets. Each tablet contains 0.45 mg of the conjugated estrogens found in Premarin tablets and 1.5 mg of medroxyprogesterone acetate for oral administration.
PREMPRO 0.625 mg/2.5 mg
Blister Card - Each carton includes 1 blister card containing 28 oval, peach tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 2.5 mg of medroxyprogesterone acetate for oral administration.
PREMPRO 0.625 mg/5 mg
Blister Card - Each carton includes 1 blister card containing 28 oval, light-blue tablets. Each tablet contains 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.
PREMPHASE therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28.
Each carton includes 1 blister pack containing 28 tablets. One blister pack contains 14 oval, maroon Premarin tablets containing 0.625 mg of conjugated estrogens and 14 oval, light-blue tablets that contain 0.625 mg of the conjugated estrogens found in Premarin tablets and 5 mg of medroxyprogesterone acetate for oral administration.
The appearance of PREMPRO tablets is a trademark of Pfizer Inc.
The appearance of PREMARIN tablets is a trademark of Pfizer Inc. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark.
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
| This product's label may have been updated. For current package insert and further product information, please visit www.pfizer.com. |
LAB-0504-7.0
March 2015
PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 0.45 mg / 1.5 mg - Blister Card
NDC 0046-1106-51
PROFESSIONAL SAMPLE – NOT FOR SALE
PREMPRO®
(conjugated estrogens/medroxyprogesterone acetate tablets)
0.45 mg / 1.5 mg
Blister card contains five tablets.
Rx only
PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 0.45 mg / 1.5 mg - POUCHES
NDC 0046-1106-51
PROFESSIONAL SAMPLE – NOT FOR SALE
PREMPRO®
(conjugated estrogens/medroxyprogesterone acetate tablets)
0.45 mg / 1.5 mg
Rx only
Visit us at www.PREMPRO.com
Package contains:
1 blister card of 5 tablets
PRINCIPAL DISPLAY PANEL - 28 Tablet 0.625 mg / 5 mg Blister Pack
START HERE
Rx only
NDC 0046-2575-12
DAY 1 → DAY 2 → DAY 3 → DAY 4 → DAY 5 → DAY 6 → DAY 7
14 maroon tablets of 0.625 mg conjugated estrogens
DAY 14 ← DAY 13 ← DAY 12 ← DAY 11 ← DAY 10 ← DAY 9 ← DAY 8
PREMPHASE® (conjugated estrogens/medroxyprogesterone acetate tablets)
DAY 15 → DAY 16 → DAY 17 → DAY 18 → DAY 19 → DAY 20 → DAY 21
14 light-blue tablets of 0.625 mg conjugated estrogens/5 mg medroxyprogesterone acetate
DAY 28 ← DAY 27 ← DAY 26 ← DAY 25 ← DAY 24 ← DAY 23 ← DAY 22